In August 2014, CarePilot USA, based in Newport Beach, California, announced a collaboration with the “Cord for Life” storage program offered by Lifeforce Cryobanks, a company based in Altamonte Springs, Florida. Through this partnership, CarePilot is now offering significant discounts on the collection, processing, and storage of newborn umbilical cord blood. Specifically, CarePilot is offering two, six, and 21-year storage plans at major discounts relative to the market rates offered by the “Cord for Life” program. [Read more…]
Hematopoietic Stem Cells (HSCs)
Top 5 Stem Cell Influencers on Twitter
Do You Know the Top 5 Stem Cell Influencers on Twitter?
Twitter is one of the most widely used social media platforms that exists. There are now 316 million monthly active users and 500 million Tweets sent per day, according to Twitter’s company statistics. In fact, every single minute of the day, there are nearly 350,000 Tweets posted to Twitter. Importantly, it is now one of the 9th most most visited website in the world, according to Alexa, an Amazon company that ranks relative traffic for websites. Within the United States, Twitter is the 8th most visited website, an absolutely incredible feat. [Read more…]
3 Eerie Similarities between the Acquisition of Cord Blood Registry® (CBR) and ViaCord
Cord Blood Registry® (CBR) recently made headlines by announcing that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals for $700M. While the announcement was new, there were aspects of the deal that seemed eerily familiar.
[Read more…]
5 Types of Cord Blood Market Participants Impacted by AMAG Pharma’s Acquisition of Cord Blood Registry (CBR®)
On June 29, 2015, AMAG Pharmaceuticals released news that reverberated throughout the cord blood banking industry worldwide, announcing that it had entered into a definitive agreement to acquire Cord Blood Registry (CBR®) for $700 million. The acquisition is expected to close during the third-quarter of 2015, based on regulatory approvals and execution of agreed upon terms and conditions.
Direct Participants in the Cord Blood Deal
Founded in 1992 and headquartered in San Bruno, California, Cord Blood Registry® is the largest cord blood bank in the United States and the world. CBR® currently stores over 500,000 preserved cord blood and cord tissue units, which is substantially more than its nearest competitor, ViaCord, which has approximately 350,000 units stored. [Read more…]
Cord Blood is 2nd Most Common Source of Stem Cells for Cell Therapy
For those competing within the cord blood marketplace, it is valuable to know that umbilical cord blood is the second most common source of stem cells for cellular therapy.
Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell-based-therapy, both for the treatment of hematological and non-hematological disorders. Indeed, with the recent expansion in stem cell research and an increase in public interest in stem cell-based therapies, researchers are now exploring the potential of umbilical cord blood stem cells for non-hematological disorders.
This is evidenced by the increasing number of clinical trials that are utilizing umbilical cord blood stem cell-based therapies to treat a range of diseases.
However, with these advances come new standards that must be established, including:
- Standardization of criteria for the selection of umbilical cord blood (UCB) units for stem cell-based therapies
- Outcome measures
- Long-term follow-up
Additionally, it is controversial within medical communities to use umbilical cord blood stem cells for non-hematological disorders, a perspective which is gradually starting to change. Clearly, therapeutic use of cord blood stem cells will play an important role in the future of regenerative medicine, but its applications and limitations of use have yet to be defined.
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- 28
- Next Page »